Business
Strategic partnership with Boca Biolistics
Strategic partnership with Boca Biolistics.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8539D\n Oxford BioDynamics PLC\n 02 November 2020\n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n \n Oxford BioDynamics announces strategic partnership with Boca Biolistics in order to advance \n \n EpiSwitch™ disease severity program for COVID-19 \n \n \n \n \n \n \n · \n Highly diverse samples will enable development of world's first 3D genomics prognostic immune health test for disease severity \n \n \n · \n US-based specialty lab \n and biorepository,\n Boca Biolistics, to provide highly diverse Covid-19 samples, including those from hardest hit territories, such as Peru, and for \"long COVID\"\n \n \n \n \n \n Oxford, UK - 2 November 2020 -\n \n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing personalized medicine tests based on 3D genomics, has entered into a strategic partnership with Boca Biolistics, a US-based biorepository, reference lab and Contract Research Organization (CRO). \n \n \n \n \n \n Under the terms of the agreement, Oxford BioDynamics will receive a\n \n diverse range of blood samples from COVID-19 patients, with detailed clinical information on disease severity. These will add to Oxford BioDynamics' existing database of 500+ UK and US samples. \n Financial details of the partnership are not disclosed.\n \n \n \n \n \n \n Oxford BioDynamics requires the widest diversity of samples as possible, depicting the broadest possible range of severity levels expressed in patients, to support product development of its EpiSwitch™\n \n \n prognostic immune-response test. Therefore, Boca Biolistics is prospectively procuring samples for Oxford Biodynamics from the US and the Caribbean, as well as South America. \n \n \n \n \n \n The underlying aim of Oxford BioDynamics is the development of a disease severity test leveraging off the Company's proprietary EpiSwitch™ technology. The 3D structure of a patient's genome contains over 1 million molecular regulatory data points1. These can be interrogated from a patient's blood using the EpiSwitch™ technology to determine what makes certain patients particularly vulnerable to hyperinflammation and severe side effects when exposed to Covid-19 infection. Based on this data, the Company is developing a panel of risk profiles to offer commercial tests...